Dr. Frederick Min has extensive experience as a clinical investigator and drug developer. After his internal medicine training from Cornell, he proceeded to combined Clinical Pharmacology and Oncology fellowship from NIH and Georgetown University Medical Center. He has published and presented over 20 abstracts and articles in ASCO, ASH, ASCPT and FDA meetings. He has led several Phase I clinical trials as clinical investigator during the fellowship including the recently approved Treanda (Bendamustine). Most recently, he lead 5 novel therapies in different stages in the US, Europe and Asia as Global Project Leader at Novartis as Medical Director. There he also served as a committee member in Target Identification Committee which is a global initiative project to identify critical novel targets with the goal of personalized medicine. With his extensive experience as a clinical investigator and drug developer, we believe he will bring our patients the most up to date and advanced therapies available. He is fluent in Korean.
Dr. Min was recently honored with the Rises award from Washington Adventist Hospital, and was named one of “America’s Top Oncologists” for 2010 by the Consumers’ Research Council of America.